Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system

Nucleic Acids Research

Volumn 30, Issue 16, 2002, Pages 3632-3641

  Hu, Qiang ^a,c   Bally, Marcel B ^b   Madden, Thomas D ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Inex Pharmaceuticals Corporation   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DRUG CARRIER; FLUORESCEIN ISOTHIOCYANATE; G 3622; LIPOSOME; MESSENGER RNA; OBLIMERSEN; PHOSPHATIDYLETHANOLAMINE; PROTEIN BCL 2; RHODAMINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOAVAILABILITY; CELL FATE; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL NUCLEUS; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENDOSOME; GENE CONTROL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; INCUBATION TIME; LYSOSOME; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

EID: 0037102494     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkf448     Document Type: Article

References (45)

1. Specific regulation of gene expression by antisense, sense and antigen nucleic acids
2. Therapeutic applications of oligonucleotides
3. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
4. Antisense approaches enter the clinic
5. Antisense therapy in oncology: New hope for an old idea?
6. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides
7. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes
8. Novel mechanisms for antisense-mediated regulation of gene expression
9. Molecular mechanisms of action of antisense drugs
10. Cellular uptake and intracellular fate of antisense oligonucleotides
11. Poor cellular uptake of antisense oligodeoxynucleotides: An obstacle to their use in chronic myeloid leukaemia
12. Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine
13. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity
14. Poly(ethylene glycol)-lipid conjugates promote bilayer formation in mixtures of non-bilayer-forming lipids
15. Spontaneous interbilayer transfer of phospholipids: Dependence on acyl chain composition
16. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: Enhanced cellular uptake and biological effects
17. Production of large unilamellar vesicles by a rapid extrusion procedure: Characterization of size distribution, trapped volume and ability to maintain a membrane potential
18. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles
19. Intracellular localization of oligonucleotides: Influence of fixative protocols
20. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT
21. RT-PCR and mRNA quantitation
22. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids
23. Phosphorothioate oligodeoxynucleotides dissociate from cationic lipids before entering the nucleus
24. Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems
25. Efficient cationic lipid-mediated delivery of antisense oligonucleotides into eukaryotic cells: Down-regulation of the corticotropin-releasing factor receptor
26. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
27. Delivery of an anti-HIV ribozyme into HIV-infected cells via cationic liposomes
28. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
29. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
30. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
31. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
32. Phase I clinical and pharmacokinetic study of bc1-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
33. Characterization of oligonucleotide transport into living cells
34. Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors?
35. Binding, uptake and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides
36. Interbilayer transfer of phospholipid-anchored macromolecules via monomer diffusion
37. Mechanism of oligonucleotide release from cationic liposomes
38. Membrane fusion plays an important role in gene transfection mediated by cationic liposomes
39. Intracellular disposition and metabolism of fluorescently labeled unmodified and modified oligonucleotides microinjected into mammalian cells
40. Characterization of liposomal drug delivery systems utilizing cell culture methods
41. Liposome-cell interactions in vitro: Effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes
42. Membrane perturbation and the mechanism of lipid-mediated transfer of DNA into cells
43. Pore-forming peptides induce rapid phospholipid flip-flop in membranes
44. Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro
45. Nuclear location of ribonuclease H and increased level of magnesium-dependent ribonuclease H in rat liver on thioacetamide treatment